We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Amplia Therapeutics is a biotechnology business based in Australia. Amplia Therapeutics shares (ATX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Amplia Therapeutics has a trailing 12-month revenue of around $2 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Overall broker
Our top pick for
Low-cost broker
| 52-week range | $0.09 - $0.25 |
|---|---|
| 50-day moving average | $0.1176 |
| 200-day moving average | $0.1579 |
| Target price | $0.73 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.025 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.096
| 1 week (2022-06-24) | -2.04% |
|---|---|
| 1 month (2022-06-02) | -26.15% |
| 3 months (2022-04-01) | -31.43% |
| 6 months (2021-12-31) | -41.82% |
| 1 year (2021-07-02) | -57.33% |
|---|---|
| 2 years (2020-07-02) | -16.96% |
| 3 years (2019-07-02) | 1.05% |
| 5 years (2017-06-30) | -98.45% |
| Revenue TTM | $2 million |
|---|---|
| Gross profit TTM | $1.8 million |
| Return on assets TTM | -12.88% |
| Return on equity TTM | -22.64% |
| Profit margin | -183.74% |
| Book value | 0.113 |
| Market capitalisation | $20.4 million |
TTM: trailing 12 months
We're not expecting Amplia Therapeutics to pay a dividend over the next 12 months.
Amplia Therapeutics's shares were split on a 1:10 basis on 30 April 2018. So if you had owned 10 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Amplia Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Amplia Therapeutics shares which in turn could have impacted Amplia Therapeutics's share price.
Over the last 12 months, Amplia Therapeutics's shares have ranged in value from as little as $0.09 up to $0.25. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Amplia Therapeutics's is 0.4907. This would suggest that Amplia Therapeutics's shares are less volatile than average (for this exchange).
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
